Johnson & Johnson (NYSE:JNJ) Vision announced that, after winning FDA approval, it launched the Tecnis Toric II one-piece intraocular lens (IOL) to treat astigmatism in cataract patients.
The Tecnis Toric II IOL is Johnson & Johnson Vision’s first approved product within the Tecnis Toric II platform, which offers more surface texture and friction on IOL haptics, which hold an IOL in position within the eye, according to a news release. It is designed to deliver visual improvement for different visual conditions and lifestyles.
Having won approval, the Tecnis Toric II one-piece and the Tecnis Toric II one-piece IOL posterior chamber lenses are indicated for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire improved uncorrected distance vision, reduction in residual refractive cylinder, and increased spectacle independence for distance vision.
Following the approval and launch, Johnson & Johnson Vision said it is launching two post-market clinical trials to demonstrate the product’s rotational stability and visual outcomes. The trials are slated to be held at up to 50 sites across the U.S. with up to 1,000 patients set to be enrolled.
“With the launch of Tecnis Toric II IOL, our goal is to provide surgeons with a higher degree of confidence in treating astigmatism so that more cataract patients can enjoy clear, high-quality vision,” Johnson & Johnson Vision global head of research & development Xiao-Yu Song said in the release. “This advance represents the latest addition to our Tecnis family of IOLs, building on our proud history of raising the standard of care for patients with cataracts.”
“Today’s patients with cataracts not only want clear vision but also less dependence on glasses following surgery—something that has historically been challenging to deliver for those with astigmatism,” added Empire Eye & Laser Center cataract & refractive surgeon Dr. Daniel H. Chang. “In my experience, toric IOLs can produce excellent visual outcomes, however, even small misalignments of the lens can lead to blurred vision. I’m looking forward to being part of the post-market clinical trials to further evaluate the rotational stability of Tecnis Toric II IOL in a large population of patients.”